| Literature DB >> 20658561 |
Sara M Mantila Roosa1, Yunlong Liu, Charles H Turner.
Abstract
The advent of high-throughput measurements of gene expression and bioinformatics analysis methods offers new ways to study gene expression patterns. The primary goal of this study was to determine the time sequence for gene expression in a bone subjected to mechanical loading during key periods of the bone-formation process, including expression of matrix-related genes, the appearance of active osteoblasts, and bone desensitization. A standard model for bone loading was employed in which the right forelimb was loaded axially for 3 minutes per day, whereas the left forearm served as a nonloaded contralateral control. We evaluated loading-induced gene expression over a time course of 4 hours to 32 days after the first loading session. Six distinct time-dependent patterns of gene expression were identified over the time course and were categorized into three primary clusters: genes upregulated early in the time course, genes upregulated during matrix formation, and genes downregulated during matrix formation. Genes then were grouped based on function and/or signaling pathways. Many gene groups known to be important in loading-induced bone formation were identified within the clusters, including AP-1-related genes in the early-response cluster, matrix-related genes in the upregulated gene clusters, and Wnt/β-catenin signaling pathway inhibitors in the downregulated gene clusters. Several novel gene groups were identified as well, including chemokine-related genes, which were upregulated early but downregulated later in the time course; solute carrier genes, which were both upregulated and downregulated; and muscle-related genes, which were primarily downregulated.Entities:
Mesh:
Substances:
Year: 2011 PMID: 20658561 PMCID: PMC3179310 DOI: 10.1002/jbmr.193
Source DB: PubMed Journal: J Bone Miner Res ISSN: 0884-0431 Impact factor: 6.741
Fig. 1Flow diagram of the array analysis methods.
Fig. 2Active osteoblasts were observed on the periosteal surface in H&E-stained cross sections of the loaded ulnar midshaft at 4 days. (Bottom) Cross sections of representative loaded ulnae at 1 day (left) and 4 days (right) (×5). (Top) Close-up images of the periosteal surface on the medial side of loaded ulnae at 1 day (left) and 4 days (right) (×40). Many active osteoblasts and osteoid were present on the bone surface at 4 days, which indicated that new bone was being formed.
Fig. 3The amount of total RNA isolated from loaded bones was significantly greater than the amount of total RNA isolated from control bones at all time points except 2 days. A paired t test was used to compare RNA quantities in loaded and control ulnae from matched RNA samples (ap value < .05). Standard errors are indicated.
Fig. 4Col1a1 expression increased in loaded ulnae at 1, 6, 8, 12, and 32 days. qPCR was used to evaluate Col1a1 gene expression in loaded and control ulnae across the time course. Col1a1 expression was normalized to β-actin expression to facilitate comparison among samples. A paired t test was used to compare expression in loaded and control conditions (ap < .05). Standard errors are indicated.
Fig. 5Six clusters were defined using a k-means clustering algorithm. Genes in the early response cluster (n = 88) were upregulated primarily at 4 hours. Expression of genes in the matrix-formation (up) clusters peaked between 12 and 16 days, and this cluster was subdivided into three magnitudes: high (n = 23), medium (n = 182), and low (n = 308). Expression of genes in the matrix-formation (down) clusters peaked at 16 days, and this cluster was subdivided into two magnitudes: high (n = 124) and low (n = 326).
Selected Gene Groups Present in the Early-Response Cluster, Which Were Upregulated 4 Hours After a Single Loading Session
| Gene group | Gene name |
|---|---|
| AP-1 | |
| | Fos-like antigen 1 |
| | Jun B protooncogene |
| Calcium signaling | |
| | Annexin A2 |
| | S100 calcium-binding protein A4 |
| | S100 calcium-binding protein A10 |
| Chemokine | |
| | Chemokine-binding protein 2 |
| | Chemokine (C–C motif) ligand 2 |
| | Chemokine (C–C motif) ligand 7 |
| | Chemokine (C–X–C motif) ligand 1 |
| | Chemokine (C–X–C motif) ligand 13 |
| Cytokine | |
| | Interleukin 1 receptor–like 1 |
| | Interleukin 1 receptor–like 2 |
| | Oncostatin M |
| | Oncostatin M receptor |
| | Suppressor of cytokine signaling 3 |
| | Signal transducer and activator of transcription 3 |
| | Tumor necrosis factor receptor superfamily, member 12A |
| Matrix | |
| | ADAM metallopeptidase with thrombospondin type 1 motif |
| | Extracellular matrix protein 1 |
| | Serine (or cysteine) peptidase inhibitor, clade A, member 3N |
| | Serpin peptidase inhibitor, clade E, member 1 |
| | Tissue factor pathway inhibitor 2 |
| Other | |
| | Cyclin d2 |
| | Chloride intracellular channel 1 |
| | G protein–coupled receptor 1 |
| | Potassium voltage-gated channel, Isk-related subfamily, gene 4 |
| | Leptin |
| | Syndecan 4 |
Selected Gene Groups Present in the Bone-Formation (Up) Clusters, Which Were Upregulated During Matrix Formation
| Gene group | Cluster | Gene name |
|---|---|---|
| Apoptosis | ||
| | L | Apoptosis-inducing factor, mitochondrion-associated 3 |
| | L | BCL2-related ovarian killer |
| | L | Defender against cell death 1 |
| Calcium signaling | ||
| | L | ATPase, Ca2+ transporting, plasma membrane 2 |
| | M | Calcium channel, voltage-dependent, β3 subunit |
| | M | Ca2+-dependent secretion activator |
| | M | Calumenin |
| | M | Calpain 6 |
| | L | Feline leukemia virus subgroup C cellular receptor family, member 2 |
| | L | Hippocalcin-like 1 |
| | L | Stanniocalcin 1 |
| | L | Synaptotagmin III |
| Cytokine | ||
| | L | Interleukin 4 |
| | L | Interleukin 11 |
| | M | Interleukin 12a |
| | L | Suppressor of cytokine signaling 2 |
| Growth factor | ||
| | L | Fibroblast growth factor 14 |
| | L | Platelet-derived growth factor α polypeptide |
| | M | Platelet-derived growth factor C |
| | M | Platelet-derived growth factor receptor–like |
| | L | Placental growth factor |
| Ion channel | ||
| | M | Potassium voltage-gated channel, Isk-related subfamily, gene 3 |
| | L | Potassium voltage-gated channel, subfamily G, member 3 |
| | M | Potassium inwardly rectifying channel, subfamily K, member 6 |
| | M | Potassium large conductance calcium-activated channel, subfamily M, α member 1 |
| | M | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| | L | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 |
| | L | Sodium channel, voltage-gated, type I, α |
| Matrix | ||
| | H | Aggrecan |
| | M | Alkaline phosphatase, liver/bone/kidney |
| | M | Bone γ-carboxyglutamate (gla) protein (osteocalcin) |
| | M | Biglycan |
| | M | Collagen, type I, α2 |
| | M | Collagen, type II, α1 |
| | M | Collagen, type III, α1 |
| | H | Collagen, type V, α1 |
| | H | Collagen, type XI, α2 |
| | M | Collagen, type XVI, α1 |
| | H | Collagen triple-helix-repeat-containing 1 |
| | L | EGF-containing fibulin-like extracellular matrix protein 2 |
| | M | Fibronectin 1 |
| | M | Integrin-binding sialoprotein |
| | H | Leucine proline–enriched proteoglycan (leprecan) 1 |
| | H | Lysyl oxidase |
| | M | Matrix metallopeptidase 2 |
| | M | Matrix metallopeptidase 9 |
| | M | Matrix metallopeptidase 14 |
| | M | Matrix metallopeptidase 16 |
| | M | Matrix metallopeptidase 23 |
| | M | Osteomodulin |
| | M | Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), α polypeptide I |
| | M | Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), α polypeptide III |
| | M | Prolyl 4-hydroxylase, β polypeptide |
| | M | Procollagen C-endopeptidase enhancer |
| | M | Procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 |
| | M | Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
| | L | Secreted protein, acidic, cysteine-rich (osteonectin) |
| | H | TIMP metallopeptidase inhibitor 1 |
| | H | Versican |
| Muscle | ||
| | M | Myosin Ib |
| | M | Myosin Va |
| | L | Tropomyosin 4 |
| | L | Tubulin, α3A |
| Neurotransmitter | ||
| | L | Dopamine receptor D1A |
| | L | Glycine receptor, β |
| | L | 5-Hydroxytryptamine (serotonin) receptor 1D |
| | M | 5-hydroxytryptamine (serotonin) receptor 2A |
| | L | synapsin I |
| Solute Carrier | ||
| | L | solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 |
| | M | solute carrier family 2 (facilitated glucose transporter), member 13 |
| | L | solute carrier family 5 (sodium iodide symporter), member 5 |
| | M | Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| | M | Solute carrier family 6 (neutral amino acid transporter), member 15 |
| | L | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 |
| | M | Solute carrier family 8 (sodium/calcium exchanger), member 3 |
| | H | Solute carrier family 9 (sodium/hydrogen exchanger), member 2 |
| | M | Solute carrier family 9 (sodium/hydrogen exchanger), member 4 |
| | H | Solute carrier family 13 (sodium-dependent citrate transporter), member 5 |
| | L | Solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1 |
| | L | Solute carrier family 26 (sulfate transporter), member 2 |
| | M | Solute carrier family 30 (zinc transporter), member 4 |
| | M | Solute carrier family 31 (copper transporters), member 1 |
| | L | Solute carrier family 35, member B1 |
| | M | Solute carrier family 36 (proton/amino acid symporter), member 1 |
| | H | Solute carrier family 36 (proton/amino acid symporter), member 2 |
| | M | Solute carrier family 39 (zinc transporter), member 7 |
| | M | Solute carrier family 39 (metal ion transporter), member 8 |
| | L | Solute carrier organic anion transporter family, member 3a1 |
| TGF-β signaling | ||
| | M | BMP and activin membrane–bound inhibitor |
| | L | Bone morphogenetic protein 2 |
| | L | Hepatocyte nuclear factor 4, α |
| | L | Inhibin β-A |
| | L | NK2 transcription factor related, locus 5 |
| | M | SMAD family member 9 |
| | L | Transforming growth factor, β1 |
| | L | Transforming growth factor, β3 |
| | L | Vitamin D (1,25-dihydroxyvitamin D3) receptor |
| Wnt/β-catenin signaling | ||
| | M | Cadherin 2 |
| | H | Carboxypeptidase Z |
| | M | Gap junction protein, α1 |
| | M | Kringle-containing transmembrane protein 1 |
| | M | Wnt inhibitory factor 1 |
| | M | Wnt1 inducible signaling pathway protein 1 |
| Other | ||
| | M | Cyclin D1 |
| | H | cAMP-responsive element–binding protein 3-like 1 |
| | L | Forkhead box S1 |
| | L | Hypoxia-inducible factor 1, α subunit |
| | L | Jun D protooncogene |
| | M | Parathyroid hormone receptor 1 |
| | L | SRY (sex-determining region Y)-box 11 |
| | M | Sp7 transcription factor (osterix) |
H = high-magnitude cluster; M = medium-magnitude cluster; L = low-magnitude cluster.
Selected Gene Groups Present in the Bone-Formation (Down) Clusters, Which Were Downregulated During Matrix Formation
| Gene group | Cluster | Gene name |
|---|---|---|
| Calcium signaling | ||
| | H | Aspartate-β-hydroxylase |
| | L | Calcium-binding protein 39-like |
| | H | Calbindin 2 |
| | H | Calcium/calmodulin-dependent protein kinase (CaM kinase) IIβ |
| | H | Calsequestrin 2 |
| | H | Parvalbumin |
| | L | Stanniocalcin 2 |
| | H | Triadin |
| Cell cycle | ||
| | L | Cyclin A2 |
| | L | Cyclin B1 |
| | L | Cell division cycle 25 homologue B |
| | L | Centromere protein C1 |
| Chemokine | ||
| | L | Chemokine (C–C motif) ligand 11 |
| | L | Chemokine (C–C motif) receptor 1 |
| | L | Chemokine (C–C motif) receptor 2 |
| | L | Chemokine (C–C motif) receptor 3 |
| | L | Chemokine (C–X–C motif) ligand 12 |
| | H | Chemokine (C–X–C motif) ligand 14 |
| | L | Chemokine (C–X–C motif) receptor 5 |
| Cytokine | ||
| | H | Ankyrin repeat and SOCS box-containing 2 |
| | L | Interleukin 8 receptor, β |
| | H | Tumor necrosis factor (ligand) superfamily, member 10 (TRAIL) |
| | L | Tumor necrosis factor receptor superfamily, member 14 |
| Growth factor | ||
| | L | Epidermal growth factor |
| | L | Fibroblast growth factor 1 |
| | H | Fibroblast growth factor 7 |
| | H | Fibroblast growth factor 23 |
| | H | Fibrinogen-like 2 |
| | L | Hepatocyte growth factor |
| | L | Insulin-like growth factor–binding protein 6 |
| Ion channel | ||
| | H | Calcium channel, voltage-dependent, β1 subunit |
| | H | Calcium channel, voltage-dependent, γ subunit 1 |
| | H | Calcium channel, voltage-dependent, γ subunit 7 |
| | L | Chloride channel calcium activated 2 |
| | L | Chloride intracellular channel 5 |
| | L | Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 |
| | L | Potassium inwardly rectifying channel, subfamily J, member 3 |
| | H | Potassium inwardly rectifying channel, subfamily J, member 11 |
| | H | Potassium inwardly rectifying channel, subfamily J, member 12 |
| | L | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| | L | Sodium channel and clathrin linker 1 |
| | H | Sodium channel, voltage-gated, type 4, α subunit |
| | H | Sodium channel, type IV, β |
| | L | Sodium channel, voltage-gated, type VII, α |
| Matrix | ||
| | H | EGF-containing fibulin-like extracellular matrix protein 1 |
| | L | Matrix metallopeptidase 8 |
| | L | Proline arginine–rich end leucine-rich repeat protein |
| | L | Serine (or cysteine) peptidase inhibitor, clade B, member 2 |
| | L | Spondin 1 |
| Muscle | ||
| | H | Actin, α1 |
| | H | Actinin, α3 |
| | H | Adenosine monophosphate deaminase 1 (isoform M) |
| | H | Desmin |
| | H | Dystrophin, muscular dystrophy |
| | H | Glycogenin 1 |
| | H | Myoglobin |
| | H | Myosin, light polypeptide 1 |
| | H | Myosin light chain kinase 2 |
| | H | Myosin light chain, phosphorylatable, fast |
| | H | Myocardin |
| | H | Small muscle protein, X-linked |
| | H | Synemin |
| | H | Troponin I type 2 |
| | H | Troponin T type 3 |
| | L | Tropomyosin 2 |
| Neurotransmitter | ||
| | H | Cholinergic receptor, nicotinic, α1 |
| | H | Cholinergic receptor, nicotinic, β1 |
| | H | Cholinergic receptor, nicotinic, ɛ |
| | L | 5-Hydroxytryptamine (serotonin) receptor 1B |
| | L | Monoamine oxidase B |
| Solute carrier | ||
| | H | Solute carrier family 2 (facilitated glucose transporter), member 1 |
| | L | Solute carrier family 4 (anion exchanger), member 1 |
| | L | Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| | L | Solute carrier family 6 (neurotransmitter transporter), member 20 |
| | L | Solute carrier family 14 (urea transporter), member 1 |
| | L | Solute carrier family 15 (H+/peptide transporter), member 2 |
| | L | Solute carrier family 16, member 1 (monocarboxylic acid transporter 1) |
| | H | Solute carrier family 16, member 3 (monocarboxylic acid transporter 4) |
| | L | Solute carrier family 16, member 6 (monocarboxylic acid transporter 7) |
| | H | Solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
| | L | Solute carrier family 25 (mitochondrial carrier, oxoglutarate carrier), member 11 |
| | L | Solute carrier family 25, member 30 |
| | L | Solute carrier family 38, member 1 |
| | L | Solute carrier family 38, member 3 |
| | H | Solute carrier organic anion transporter family, member 1a4 |
| TGF-β signaling | ||
| | H | Bone morphogenetic protein receptor, type IB |
| | L | Chordin-like 1 |
| | H | Gremlin 1, cysteine knot superfamily |
| | L | Transforming growth factor, β receptor III |
| Ubiquitin | ||
| | L | Ubiquitin-specific peptidase 1 |
| | L | Ubiquitin-specific peptidase 15 |
| Wnt/β-catenin signaling (inhibitors) | ||
| | H | Secreted frizzled-related protein 4 |
| | L | Sclerosteosis |
| Other | ||
| | H | Adrenergic, β2, receptor, surface |
| | L | Caspase 1 |
| | L | Ficolin (collagen/fibrinogen domain containing) 1 |
| | L | Leptin receptor |
| | L | Musculoskeletal, embryonic nuclear protein 1 |
| | L | Prostaglandin D2 synthase 2, hematopoietic |
| | L | Radical |
H = high-magnitude cluster; L = low-magnitude cluster.